Greg is a seasoned entrepreneur who has over 20 years of experience in the Executive Search and Management consulting field through his company HEC GROUP. He specializes in building high performance teams for his clients in the automotive, food, pharma and chemical industries. For the past 3 years, Greg has applied his talents to the rapidly emerging medical Cannabis industry as an investor and trusted advisor to companies throughout the world looking to enter this space. Greg is the founder of Dosecann, and did so to address the need for accurate, safe and reliable delivery mechanisms for Medical Cannabis.
Nitin has 30 years of experience in healthcare, financial and investment banking. His area of expertise is in the pharmaceutical, consumer healthcare, healthcare services and medical device industries. Nitin has held senior roles in venture capital, investment banking, M&A, technology licensing, auditing and consulting. He has been involved in over 40 successful M&A, strategic advisories and licensing assignments for a range of companies from early stage biotechs to large pharmas. He has participated in capital market transactions In excess of $2B. Nitin sits on several private and public company boards.
Jeff is the president and founder of New Horizon Development Group. He is also Chairman of the Board of ACMPR Licensed Producer, The Green Organic Dutchman. In 2013 he was named RBC Distinguished Citizen of the Year for Hamilton. Jeff is very active in the home building industry as a past president of the Hamilton Halton Home Builders’ Association and a former board member of both the Ontario Home Builders’ Association and the Canadian Home Builders’ Association. Jeff is a member of the Hamilton Tiger Cats advisory board and the Hamilton Bulldogs Community Foundation board. He is the current Chair of the Hillfield Strathallan College Capital Campaign and past Chair of the board of both Hillfield Strathallan College and the Canadian Accredited Independent Schools (CAIS.ca).
Scott is a Director, Supreme Pharma Inc – ($SL.C | >$250m mkt cap), which is a Health Canada licensed wholesale producer of medical cannabis under ACMPR. Supreme grows under contract for six of the leading medical cannabis brands in Canada. Scott is former CEO, co-founder of CMClinic.ca ($CMM.V on TSXV), a leading Canadian medical cannabis clinic. CMClinic.ca is now helping over 12,000 Canadians with free medical care using cannabinoid therapy and is supported by research grants from 6 of the leading medical cannabis brands in Canada. He is the former CEO and business plan developer of THCBioMed ($THC.C | > $100m mkt cap) which was the 29th producer of cannabis to be licensed for sale of cannabis and oil under the ACMPR.
Mike is an experienced executive with more than 30 years of proven experience building and leading teams, increasing market share, and reducing costs. He has a people-focused leadership style that empowers teams to deliver results and reach goals. Mike is highly adaptable with excellent creative problem solving skills and ability to design and execute effective solutions for unique business challenges. Mike spent 10 years at UNFI (United Natural Foods), America’s largest distributor of Organic, Natural and specialty products. He held several roles with the company, with his last one being President. After UNFI, Mike spent 6 years as CEO of Lang Pharma Nutrition, a private label manufacture for CVS, Walgreens and Costco, where he led them to 6X growth.
Dr. Joseph Gabriele Ph.D. Chairman of Scientific Board
Dr.Joseph Gabriele, Ph.D., is a molecular pharmacologist specializing in fields of transdermal delivery, formulation chemistry with pharmaceutical, natural molecules, and signal transduction pathways in numerous disease states. He lectures on these topics across North America. Dr. Gabriele is the founder, inventor and visionary behind the Delivra™ technology. Dr. Gabriele has devoted the past eight years to innovation, development, and commercialization activities at Delivra, and in addition to providing guidance and vision for Delivra, he actively stewards its robust R&D program. He has a doctorate in molecular pharmacology and is an Assistant Professor (PT), McMaster University, Department of Psychiatry and Behavioral Neurosciences, as well as Special Graduate Faculty, University of Guelph, Department of Biomedical Sciences. Dr. Gabriele received a B.Sc. from the University of Toronto, with M.Sc. and Ph.D. degrees from McMaster University. Dr. Gabriele’s Ph.D. training was conducted under Dr. R.K. Mishra, focusing on molecular pharmacology/neuroscience and its implications in psychiatric and neurological disorders. He has received numerous awards, including a CIHR studentship award in pharmacology during his M.Sc. degree; an NSERC Canada Graduate Scholarship during his Ph.D. training; and the International Congress on Schizophrenia Research, Young Investigator Award. From 2012, Dr. Gabriele has been awarded over $5,000,000.00 in grants and loans from the Canadian Federal and provincial governments for his work at Delivra Corp. Dr. Gabriele has extensive experience in start-up companies that commercialize products for medical sciences and the health care industry.
Dr. Mehrdad Barghian Ph.D., M.Phil., QPIC, C.Chem.
“The most important thing is to always be open to ideas, and to think outside the box without compromising product quality, safety, and regulatory requirements” Dr. Barghian is the President and Chief Executive Officer of ARA – Avanti Rx Analytics Inc., located in Ontario, Canada where he leads a team of highly skilled scientist and regulatory professionals dedicated to conducting analytical quality control, R&D, QA, RA, extraction, and purification on cannabinoids. Dr. Barghian leverages background in organic synthesis, analytical chemistry, terpene science, and long standing experience in pharmaceutical quality control, quality assurance and regulatory affairs. Dr. Barghian is also the lead researcher conducting clinical studies on effects of CBD and CBG on mammalian cancer in collaboration with University of Georgia, school of medicine, Georgia, USA. His earlier career as a pharmaceutical R&D and Quality Control leader included positions with Genpharm (now known as Mylan), Apotex, Ciba Vision (now known as Alcon), and Aventis Pasteur (now known as Sanofi Pasteur). Dr. Barghian earned his M.Phil. and Ph.D. in organic synthesis and analytical Chemistry from University of Cardiff, Wales, United Kingdom, and completed his CRC (Cancer Research Campaign) Post-doctoral research at the Queen Mary Westfield College, University of London, England. Dr. Barghian is the president of the International Pharmaceutical Academy (IPA) and lectures throughout the world on numerous GMP compliance, validation, and analytical testing related matters.
Joseph Araujo, Ph.D (c)
Joeseph is President and CEO of InterVivo Solutions focused on optimizing the translational value of InterVivo’s services to facilitate the development and approval of novel drugs. Joseph continues to be closely involved in projects utilizing, characterizing and developing the aged dog as a natural model of age-related human diseases. He is a strong proponent for the use of validated natural and/or translational animal models in drug discovery and in collaborative development models. His scientific background includes graduate training in behavioral pharmacology at the University of Toronto, more than 35 refereed publications and several invited presentations, which exemplifies his continued passion for scientific innovation and expertise in natural aged canine models of human disease, and particularly forward and back translation of Alzheimer’s disease using the naturalistic aged canine model of Alzheimer’s disease progression. Joseph directly supports developing biotech talent and their related companies and has co-founded and held executive level positions in several Contract Research, Life Science and Animal Health companies helping to build their global presence and success. Specifically, these include: CanCog Technologies, Karyopharm Therapeutics, NPM Pharma, Ketogen and Epione Animal Health.
Dr. Perry Mayer M.D.
Dr. Perry Mayer M.D. is the Medical Director of The Mayer Institute (TMI), a centre of excellence for the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University in Kingston, Ontario, Canada and medical degree from the Royal College of Surgeons in Ireland. He returned to Kingston in 1993 to practice family medicine and establish the Quarry Foot Clinic. In 2003, Dr. Mayer moved to Hamilton, Ontario and concentrated his time solely on the treatment of the diabetic foot. He formed TMI in 2006. In the past year, The Mayer Institute had over 15,000 patient visits, with over 10,000 visits being for diabetic wound care. Dr. Mayer’s current research projects include a national, multicentre trial investigating the effect of human amniotic membrane on the healing of diabetic foot ulcers and ongoing research into the use of a novel transdermal delivery system to manipulate the wound environment of diabetic foot ulcers.
Dr. Patrick Gunning, Ph.D.
Dr.Patrick Gunning received a B.S. degree (with Honors) in chemistry in 2001 from the University of Glasgow. He obtained a Ph.D. in organic chemistry from the University of Glasgow in 2005. He was a Postdoctoral Research Associate at Yale University between 2005 and 2007. In September 2007 he accepted a position as an Assistant Professor of Chemistry at the University of Toronto. Dr. Gunning has authored or coauthored 65 research publications, and been an inventor of record on 10 U.S. Patents. To date, Dr. Gunning’s work has been featured on 10 journal covers. Dr. Gunning is the recipient of the Connaught Award, David Rae Memorial Award for innovative research by the Leukemia Lymphoma Society, the Ontario Early Researcher Award, the Boehringer Ingelheim Young Investigator Award (in organic chemistry), the 2010 University of Glasgow Young Alumnus of the Year, the 2011, 2012 and 2013 CSC Ichikizaki award for Young Chemist and the 2011 Dean’s Research Excellence Award at University of Toronto Mississauga and was named the 2012 RSC MedChemComm Emerging Investigator Lectureship by the Royal Society for Chemistry (UK). Dr. Gunning was featured in the Toronto Star’s 2013 Top 10 to Watch. In 2013, Dr. Gunning was the recipient of the 2013 University of Toronto Inventor of the Year Award and was the inaugural winner of the Baird of Bute Society’s Young Scottish Innovator of the Year. Also in 2013, Patrick was named a Canada Research Chair in Medicinal Chemistry. In 2014, Patrick was the recipient of the NSERC Accelerator Award. In 2015, was the Rose-Winer Levin Lecurer at the Dana-Farber Medical School at Harvard University. He was also named the University of Toronto McLean Award winner. In 2016 he was named the Canadian Society for Chemistry’s Bernard Belleau award winner. In five years at the University of Toronto, Patrick has attracted over $14.1 million in research funding and is presently a full professor at the University of Toronto.
Dr. Mark Scappaticci, B.Sc., D.C., D.Ap., F.C.C.S.S.(C)
Dr. Mark Scappaticci has developed a unique treatment model that blends a number of modalities, including specialized Myofascial Release Techniques, Fascial Abrasion Technique, Bio-Medical Acupuncture, Dry Needling, and Synergy Performance Taping method to facilitate rapid recovery of injuries as well as enhance performance. Together with the Functional Integrated Testing methods, the Functional Integrated Therapy™ model helps to identify and manage barriers to performance and recovery that other methods may overlook. He has been called to consult with a number of Olympic athletes as well as professional athletes in the NHL, MLB, NBA, NFL, CFL and PGA to assist in treatment of sports injuries, and also to design and develop performance enhancement protocols. Mark has travelled with athletes such as: Donovan Bailey, Atlanta Olympic Gold Medallist and World Record holder, indoor and outdoor; Merlene Ottey, multi-medallist in the 100 m and 200 m sprints, Adam Nelson, Olympic medalist in shot put, Christian Taylor, 2011 World champion in long and triple jump, as well as a number of other elite Olympic athletes to assist in optimizing their biomechanics for performance enhancement at the track and field meets worldwide. Athletes from around the world have also travelled to his office in the Niagara Region for treatment of sports injuries and advice on how to optimize their performance. Currently, Mark is on staff with the Toronto Blue Jays MLB team as a soft tissue injury specialist, and consults with a number of professional hockey players throughout the NHL. He has developed and taught a number of programs world wide; Functional Integrated Acupuncture, Functional Integrated Dry Needling, Fascia Abrasion Technique, and Synergy Performance Taping.
Dr. David Baranowski, Ph.D.
Dr.David Baranowski joined the Delivra at the inception of its research and development laboratory in 2013. He manages the day-to-day operations of the R&D segment of the company, guiding and designing basic, pre-clinical, and clinical research with a strong focus on the regulatory pathways to product development. Dr. Baranowski also functions as human resource manager of R&D and holds an Adjunct Professor position at the University of Prince Edward Island. Dr. Baranowski has worked in the biotechnology industry for 10 years as a research scientist for various enterprises including CRP40 Inc. and Neurodyn Inc., with experience in laboratory management, methods development, and pre-clinical experimentation. His previous position as a research scientist included technical expertise associated therapeutics and diagnostics for Parkinson’s disease along with numerous bioanalytical methods and synthetic chemistry. Dr. Baranowski received his Ph.D. at McGill University investigating the in vivo function of progranulin and proprotein convertase subtilisin/kexin type 9 (PCSK9), proteins involved in dementia and wound healing and cholesterol and lipid metabolism, respectively. At present Dr. Baranowski oversees the execution of Delivra’s R&D overarching mission, to translate research from benchtop to kitchen counter.